Skip to main content

Low Anaphylaxis Risk with COVID mRNA Vaccines

Mar 12, 2021 11:04 am

JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. 

Prior studies suggested the risk of anaphylaxis to the mRNA COVID-19 vaccines may be as low as 2.5 - 11.1 cases per million doses and that such reactions are more likely in those with a history of allergy.

A prospective, post-vaccination survey study of two Boston hospital employees receiving mRNA COVID-19 vaccines between December 16th and February 12th (with follow-up 2/18/2021) were assessed for side effects, including anaphylaxis (defined by apriori criteria)

A total of 64 900 employees who received their first dose of a COVID-19 vaccine (40% Pfizer-BioNTech vaccine and 60% Moderna vaccine).

Notable side effects reported: 

  • 2.1%  Acute allergic reactions (Moderna 2.2%; Pfizer 1.95%)
  • 16 (0.025%) employees had confirmed anaphylaxis (7 cases with Pfizer-BioNTech; 9 cases Moderna vaccine) 
    • anaphylaxis occured mostly (94%) in women, 63% had a prior allergy and 5 (31%) had an anaphylaxis history.
    • Mean time to anaphylaxis onset was 17 minutes (range, 1-120).
    • All recovered and one patient was admitted to intensive care
  • It was estimated that nearly 4000 individuals with severe food or medication allergy histories were safely vaccinated.

 

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×